SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASE
Clinical trials for SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASE explained in plain language.
Never miss a new study
Get alerted when new SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASE trials appear
Sign up with your email to follow new studies for SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New study tracks how well nintedanib works over time for scleroderma lung disease
Disease control OngoingThis study follows 2,000 people with systemic sclerosis (scleroderma) who have lung disease and are taking the drug nintedanib (Ofev®). Researchers want to see how the drug affects lung function, quality of life, and survival over the long term. The study is observational, meanin…
Matched conditions: SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASE
Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
AI scans could predict lung trouble in scleroderma patients
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at whether artificial intelligence can analyze CT scans of the lungs to predict how systemic sclerosis (a rare autoimmune disease) will affect the lungs over time. Researchers will review past scans and health records of 1,000 patients to see if certain imaging f…
Matched conditions: SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASE
Sponsor: Royal Brompton & Harefield NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:11 UTC